(63) conducted a phase III ALEX study in patients with treatment-naïve stage IV ALK+ NSCLC, the result showed that compared with crizotinib, alectinib has better CNS activity, and patients with previously brain radiotherapy had higher intracranial objective response rate (86% vs 79%) and intracranial duration of response (not reached vs 17.3 months) compared with patients without previous radiotherapy. Here, ALK is linked to non-small cell lung carcinoma.